Despite being a global drugmaker, the fortunes of Mylan N.V. (NASDAQ: MYL) are tightly linked to the U.S. market. Continued headwinds in the U.S. for generic drugs caused Mylan to slash its full-year ...

It was an eventful week for Mylan N.V. (NASDAQ: MYL). The generic drugmaker received good news from an Israeli court related to its attempt to take over Perrigo (NYSE: PRGO). It launched a new drug in ...

NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: A proposed settlement (“Settlement”) has been reached in a class action lawsuit alleging that Mylan N.V., Mylan ...

Mylan N.V. and Mylan Inc. (Nasdaq: MYL) today announced the successful completion of the acquisition of Abbott Laboratories' (NYSE: ABT) non-U.S. developed markets specialty and branded generics ...

Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research ...

Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant's Targretin ® Capsules. This product is indicated for the treatment of ...

Most of the news about Mylan N.V. (NASDAQ: MYL) in 2016 has focused on the company's controversial pricing. But the drugmaker was able to change the headlines, if only for a while, when it announced ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the ...

TO: All persons and entities who purchased or otherwise acquired the publicly traded common stock of Mylan N.V. ("Mylan") from February 16, 2016 through May 7, 2019, inclusive (the "Settlement Class ...

Thank you all for joining us. We have Mylan management that will appear for this amazing weather, so thank you for being here. Maybe just to kick things off at a high level, before we jump into it, ...